MFDS Approves New Drug 'Lopressa' for Glaucoma and Ocular Hypertension
[Asia Economy Reporter Lee Gwan-ju] The Ministry of Food and Drug Safety approved on the 3rd the imported new drug 'Lopressa Ophthalmic Solution 0.02% (Netarsudil Mesylate)' from Korea Santen Pharmaceutical, which lowers intraocular pressure in glaucoma patients.
Lopressa Ophthalmic Solution is a medication that lowers intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by selectively inhibiting the enzyme that contracts trabecular meshwork cells, relaxing the trabecular pathway, the main aqueous humor outflow route, thereby increasing aqueous humor outflow and lowering intraocular pressure.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- Despite Warnings of "Do Not Enter, You May Not Make It Out Alive"... Foreign Tourist Stranded After Unauthorized Climb on Jeju Sanbangsan
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The Ministry of Food and Drug Safety stated, "This will help expand the range of treatment options used to alleviate various symptoms caused by increased intraocular pressure in patients with existing glaucoma or ocular hypertension."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
